IN2014CN03072A - - Google Patents

Info

Publication number
IN2014CN03072A
IN2014CN03072A IN3072CHN2014A IN2014CN03072A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A IN 3072CHN2014 A IN3072CHN2014 A IN 3072CHN2014A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A
Authority
IN
India
Prior art keywords
compositions
directed
production
methods
present
Prior art date
Application number
Other languages
English (en)
Inventor
Terrance A Stadheim
Daniel Cua
Dongxing Zha
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN03072A publication Critical patent/IN2014CN03072A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN3072CHN2014 2011-10-31 2012-10-26 IN2014CN03072A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553335P 2011-10-31 2011-10-31
PCT/US2012/062211 WO2013066761A1 (en) 2011-10-31 2012-10-26 Method for preparing antibodies having improved properties

Publications (1)

Publication Number Publication Date
IN2014CN03072A true IN2014CN03072A (pl) 2015-07-31

Family

ID=48192651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3072CHN2014 IN2014CN03072A (pl) 2011-10-31 2012-10-26

Country Status (9)

Country Link
US (1) US20140286946A1 (pl)
EP (1) EP2773661A4 (pl)
JP (1) JP2014532661A (pl)
KR (1) KR20140097245A (pl)
CN (1) CN104011076A (pl)
AU (1) AU2012332840A1 (pl)
CA (1) CA2853809A1 (pl)
IN (1) IN2014CN03072A (pl)
WO (1) WO2013066761A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2739280T3 (es) 2013-07-04 2020-01-30 Glykos Finland Oy Células fúngicas filamentosas deficientes en O-manosiltransferasa y métodos de uso de las mismas
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6894239B2 (ja) 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
TWI670078B (zh) 2014-05-27 2019-09-01 中央研究院 抗ｃｄ２０醣抗體及其用途
WO2015184002A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
WO2016012468A1 (en) 2014-07-21 2016-01-28 Novartis Ag Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
KR20210084695A (ko) * 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2912154B1 (fr) * 2007-02-02 2012-11-02 Glycode Levures genetiquement modifiees pour la production de glycoproteines homogenes
WO2011149999A2 (en) * 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties

Also Published As

Publication number Publication date
WO2013066761A1 (en) 2013-05-10
KR20140097245A (ko) 2014-08-06
AU2012332840A1 (en) 2014-05-15
CN104011076A (zh) 2014-08-27
EP2773661A1 (en) 2014-09-10
EP2773661A4 (en) 2015-06-17
US20140286946A1 (en) 2014-09-25
JP2014532661A (ja) 2014-12-08
CA2853809A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IN2014CN03072A (pl)
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
UA110354C2 (uk) Противірусні сполуки
MX2022000026A (es) Anticuerpos para tau.
JO3773B1 (ar) معدلات p2x7
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
IN2013MN00501A (pl)
IN2015DN00127A (pl)
IN2015DN03029A (pl)
MX337549B (es) Derivados de insulina que contienen enlaces disulfuro adicionales.
IN2015DN00372A (pl)
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
IN2014DN09450A (pl)
IN2014DN00254A (pl)
MX350392B (es) Aceite de sandalo y sus usos.
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX347541B (es) Analogos de acido sialico.
IN2013MU01113A (pl)
WO2013181599A3 (en) Methods related to rituximab
MX2013014420A (es) Composiciones en gel.
IN2013MU01290A (pl)
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.